BR112021010856A2 - Vibegron para o tratamento de sintomas de bexiga hiperativa - Google Patents

Vibegron para o tratamento de sintomas de bexiga hiperativa

Info

Publication number
BR112021010856A2
BR112021010856A2 BR112021010856A BR112021010856A BR112021010856A2 BR 112021010856 A2 BR112021010856 A2 BR 112021010856A2 BR 112021010856 A BR112021010856 A BR 112021010856A BR 112021010856 A BR112021010856 A BR 112021010856A BR 112021010856 A2 BR112021010856 A2 BR 112021010856A2
Authority
BR
Brazil
Prior art keywords
vibegron
overactive bladder
treating overactive
bladder symptoms
symptoms
Prior art date
Application number
BR112021010856A
Other languages
English (en)
Inventor
Cornelia Haag-Molkenteller
Jihao Zhou
N Mudd Paul Jr
Original Assignee
Urovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences Gmbh filed Critical Urovant Sciences Gmbh
Publication of BR112021010856A2 publication Critical patent/BR112021010856A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

vibegron para o tratamento de sintomas de bexiga hiperativa. a presente invenção refere-se a um método de tratamento de sintomas de bexiga hiperativa em homens com hiperplasia prostática benigna, compreendendo administrar oralmente a um indivíduo em necessidade de tratamento uma quantidade de cerca de 60 mg a cerca de 90 mg (por exemplo, cerca de 75 mg) de vibegron por dia.
BR112021010856A 2018-12-05 2019-12-05 Vibegron para o tratamento de sintomas de bexiga hiperativa BR112021010856A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862775818P 2018-12-05 2018-12-05
US201962830298P 2019-04-05 2019-04-05
US201962842418P 2019-05-02 2019-05-02
PCT/IB2019/060490 WO2020115705A1 (en) 2018-12-05 2019-12-05 Vibegron for the treatment of overactive bladder symptoms

Publications (1)

Publication Number Publication Date
BR112021010856A2 true BR112021010856A2 (pt) 2021-11-16

Family

ID=68965948

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021010856A BR112021010856A2 (pt) 2018-12-05 2019-12-05 Vibegron para o tratamento de sintomas de bexiga hiperativa

Country Status (15)

Country Link
US (1) US20220117971A1 (pt)
EP (1) EP3890743A1 (pt)
JP (1) JP2022510084A (pt)
KR (1) KR20210102892A (pt)
CN (1) CN113164486A (pt)
AU (1) AU2019393372A1 (pt)
BR (1) BR112021010856A2 (pt)
CA (1) CA3115190A1 (pt)
CL (1) CL2021001397A1 (pt)
IL (1) IL283031A (pt)
MX (1) MX2021003980A (pt)
PH (1) PH12021550741A1 (pt)
SG (1) SG11202103662VA (pt)
TW (1) TW202038963A (pt)
WO (1) WO2020115705A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202239412A (zh) * 2020-12-22 2022-10-16 瑞士商優洛凡特科學公司 使用維貝格隆（ｖｉｂｅｇｒｏｎ）並監測地高辛（ｄｉｇｏｘｉｎ）以治療膀胱過動症的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2156847A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor.
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
US9809536B2 (en) 2011-10-27 2017-11-07 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
PT2968269T (pt) 2013-03-15 2019-10-08 Merck Sharp & Dohme Processo para preparação de beta 3 agonistas e intermediários
CA3064989A1 (en) * 2017-06-06 2018-12-13 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
US20210077496A1 (en) * 2017-06-06 2021-03-18 Urovant Sciences Gmbh Dosing of vibegron for treatment of overactive bladder

Also Published As

Publication number Publication date
KR20210102892A (ko) 2021-08-20
US20220117971A1 (en) 2022-04-21
EP3890743A1 (en) 2021-10-13
CL2021001397A1 (es) 2021-11-26
CN113164486A (zh) 2021-07-23
SG11202103662VA (en) 2021-06-29
IL283031A (en) 2021-06-30
PH12021550741A1 (en) 2021-10-04
MX2021003980A (es) 2021-07-21
CA3115190A1 (en) 2020-06-11
JP2022510084A (ja) 2022-01-26
TW202038963A (zh) 2020-11-01
AU2019393372A1 (en) 2021-05-13
WO2020115705A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
CL2020002401A1 (es) Composiciones de arni de 17 b-hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas.
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
ECSP20024210A (es) Uso de inhibidores de p38 para reducir la expresión de dux4
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
AR067395A1 (es) Inhibicion de htra1 mediada por iarn para el tratamiento de la degeneracion macular
MX2023002325A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
EA202092748A1 (ru) Модуляторы экспрессии apol1
BR112015000808A2 (pt) regime de dosagem para inibidores de janus quinase (jak)
CO2022000270A2 (es) Inhibidores de enzimas
CL2021001246A1 (es) Moduladores de expresión irf5.
CO2022000266A2 (es) Inhibidores de enzimas
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
DOP2022000095A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax
CL2022001167A1 (es) Tratamiento de trastornos hepáticos
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer